• 1nhaler raises additional £2.2 million for development of its single-dose salbutamol (albuterol) DPI

  1nhaler announced that it has closed a £2.2 million funding round led by Archangels, with the proceeds intended to support preparations for a clinical trial of its disposable, single-dose 1nhaler Salbutamol DPI with a goal… [Read more . . .]

• Tiziana says Phase 2a trial of intranasal foralumab in patients with na-SPMS met its primary endpoints

  Tiziana Life Sciences has announced that the Phase 2a INFORM-MS study of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis met both of its primary endpoints, demonstrating significant reduction in microglial activation at Week… [Read more . . .]

• Merck initiates the Phase 3 ENHANCE-3 trial of Ohtuvarye ensifentrine inhalation suspension for the prevention of COPD exacerbations

  Merck has announced the initiation of the Phase 3 ENHANCE-3 study of Ohtuvarye ensifentrine inhalation suspension, which is expected to enroll 2,136 COPD patients and will evaluate Ohtuvarye for the prevention of exacerbations. Merck acquired… [Read more . . .]

• FDA clears IND for Phase 1 trial of United Therapeutics’ treprostinil / iloprost SMI

  Following soon after United Therapeutics’ announcement that the FDA had cleared an IND for a Phase 2 trial of the company’s treprostinil SMI in patients with PH-COPD, the company has announced an IND clearance for… [Read more . . .]

• Phase 2a trial of AerTherapeutics’ nebulized fexlamose failed to meet primary or secondary endpoints

  Aer Therapeutics has announced that a Phase 2a trial of fexlamose (AER-01) inhalation solution in patients with moderate-to-severe COPD failed to meet primary or secondary endpoints and also demonstrated an increased incidence of adverse events… [Read more . . .]

• Blue Lake gets $5 million grant from the Gates Foundation for expansion of Phase 1/2a pediatric trial of intranasal vaccine against RSV

• DDL 2026 will feature the launch of a new incubator

• Aptar Pharma acquires Pulmotree and its Kolibri mesh nebulizer

• Aptar names Virginie Maes as incoming President of Aptar Pharma

• Nano24 announces that Phase 2b trial of its EXO-CD24 inhaled exosome in ARDS met its primary endpoint

More news . . .